Shares of Afya slipped 1.8% to $13.34 as investors digested a landmark merger that will reshape Brazil's private education landscape — and force U.S.-listed shareholders into an unfamiliar exchange. Afya Bets Its Nasdaq Listing on a Brazilian Mega-Merger — Can Shareholders Trust the Synergy Math?
Shares dipped 1.8% to $13.34 after Afya signed a binding agreement to merge into Yduqs, Brazil's largest private university operator, in a deal that will erase the company from the Nasdaq and bet everything on dominating medical education in Latin America's biggest economy.
• Afya Disappears, But Its Shareholders Take the Bigger Seat. Under the agreement, Afya is absorbed into Yduqs, which survives as the combined company. Despite being the entity that legally ceases to exist, each Afya share converts into 6.408347 new Yduqs shares, leaving Afya holders with 69% of the enlarged company.
Germany's Bertelsmann, Afya's current controlling shareholder, will become the largest shareholder with about 47% of the capital and appoint a majority of the board, while Afya's CEO Virgilio Gibbon will run the combined group. In practice, the buyer is being bought.
• Some U.S. Investors Won't Get Shares — They'll Get Cash They Can't Control. The surviving entity will list exclusively on Brazil's B3 exchange, effectively removing Afya from the Nasdaq and creating significant liquidity implications for U.S.-based retail investors.
U.S. holders who aren't large institutional investors are expected to receive net cash proceeds from a post-closing sale process — meaning a broker will sell their converted shares on the Brazilian market at whatever price prevails, with no guarantees on timing or exchange rates. Neither company makes any representation about the amount or timing of those proceeds.
• R$2 Billion in Promised Savings Faces a Long, Uncertain Road. The companies project R$2.0–2.2 billion in synergies from combining two sprawling campus networks — the combined group will operate 176 campuses across all 26 Brazilian states. But the deal won't close until March 2028 at the earliest. Brazil's antitrust regulator CADE has blocked an education merger before, and the agreement includes break-up fees of R$325 million before shareholder approval and R$650 million after it. That structure signals both sides see real regulatory risk.
• The Financials Tell a Story of Strength — for Now. Afya posted R$3.7 billion in 2025 revenue, up 11.9% year over year, with adjusted EBITDA margins of 45.4%. Those are elite numbers for an education company. The question is whether bolting on Yduqs's lower-margin distance-learning business dilutes that profitability before synergies materialize. For at least 18 months, Afya shareholders will hold a stock in limbo — priced in dollars but headed for São Paulo.